Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[177Lu]Lu-XT117 in FAP-positive advanced solid tumors
NCT06211647Phase 1Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of lutetium (177Lu) lu-xt117 in solid tumor (advanced stage). Primary endpoints: Treatment emergent adverse events at 6 months, Dose-limiting toxicities at 6 weeks and 2 more. Started Jan 2024; status: recruiting.
02
Drugs
lutetium (177Lu) lu-xt117
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT06211647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06211647.